Associated Papers
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N et al.
Thoracic Cancer, 2025
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV et al.
International Journal of Molecular Sciences, 2023
37686200 (PubMed )
Supplement: ijms-24-13390-s001.zip › ijms-2558089-supplementary.pdf
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_2.xlsx › EGFR_Mutations
Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA.
Pasini L et al.
Molecular Oncology, 2021
Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C et al.
Molecular Medicine Reports, 2018
Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.
Su J et al.
Oncotarget, 2017
Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population.
Trachu N et al.
Oncotargets and Therapy, 2017
Cytosine deamination is a major cause of baseline noise in next-generation sequencing.
Chen G et al.
Molecular Diagnosis & Therapy, 2014
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Pircher A et al.
Lung Cancer (amsterdam, Netherlands), 2014
Select a paper to view details